Diranersen Shows Growing Benefit at Two Years in Early Alzheimer's
BIIB sits 58% above its 52-week low of $160.365.
Summary
Biogen's tau-targeting antisense therapy diranersen showed increasing clinical benefit at two years in the Phase 2 CELIA study, with the 60 mg twice-yearly regimen producing the largest effects. The CDR-SB treatment effect grew from 26% at Week 76 to 38% at Week 96, a 1.09-point difference that clears the one-point threshold clinicians consider meaningful. ADAS-Cog13 separation widened from 42% to 54%, and function measures improved as well, with no new safety signals through two years. The data were presented at CTAD 2026 and support advancing diranersen into Phase 3; the drug holds FDA Fast Track designation but remains investigational. This is a pipeline readout, not a commercial event, so the near-term stock impact depends on how much credibility the market assigns to a Phase 2 tau program ahead of pivotal testing.
At the time of this announcement, BIIB was trading at $253.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.1B. The 52-week trading range was $160.36 to $261.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.